Cowen & Co. Sticks to Their Hold Rating for PTC Therapeutics

By Austin Angelo

Cowen & Co. analyst Ritu Baral reiterated a Hold rating on PTC Therapeutics (NASDAQ: PTCT) today. The company’s shares opened today at $18.33, close to its 52-week high of $18.86.

Baral wrote:

“Yesterday, PTCT presented at the PPMD conference and provided an update on.”

According to TipRanks.com, Baral is a 5-star analyst with an average return of 14.2% and a 49.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Global Blood Therapeutics, and Intra-Cellular Therapies.

PTC Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.33.

The company has a one year high of $18.86 and a one year low of $4.03. Currently, PTC Therapeutics has an average volume of 909.1K.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PTCT in relation to earlier this year. Last month, Mark Rothera, the CCO of PTCT bought 2,000 shares for a total of $21,700.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PTC Therapeutics, Inc. engages in the discovery, development, and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology. Its preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology and infectious disease.